TY - JOUR
T1 - Peripheral delta opioid receptors require priming for functional competence in vivo
AU - Rowan, Matthew P.
AU - Ruparel, Nikita B.
AU - Patwardhan, Amol M.
AU - Berg, Kelly A.
AU - Clarke, William P.
AU - Hargreaves, Kenneth M.
N1 - Funding Information:
The authors would like to thank Dharshini Amarneethi for excellent technical assistance. This work was supported by USPHS grant P01DA016719, a Research Support Grant award from the Oral and Maxillofacial Surgery Foundation, the Texas Advanced Research Program under Grant No. 3659-0023, and COSTAR Training Grant NIDCR T32DE14318 (M.P.R.).
PY - 2009/1/14
Y1 - 2009/1/14
N2 - Although centrally acting opioid analgesics produce profound antinociception under basal conditions, the antinociceptive properties of peripherally restricted opioid analgesics are generally only detectable after inflammation or injection of inflammatory mediators. Despite considerable research, the cellular mechanisms regulating the functional competence of peripheral opioid receptor systems for inhibition of nociception remain unclear. Recent work has demonstrated that brief pre-treatment (priming) with bradykinin, arachidonic acid, protease-activated receptor-2 agonists, or direct activators of protein kinase C (PKC) are capable of inducing the functional competence of the opioid receptor system in cultures of primary sensory neurons in vitro. Here we report that the peripheral delta opioid receptor system also requires PKC-dependent priming to inhibit prostaglandin E2 (PGE2)-induced thermal allodynia in the rat. Peripheral hindpaw injection of [D-Pen2,5]-enkephalin (DPDPE), a selective delta opioid receptor agonist, did not alter PGE2-induced thermal allodynia. However, following priming (15 min) with bradykinin or arachidonic acid, DPDPE produced a significant reduction in allodynia that was antagonist reversible, peripherally restricted, and exhibited a typical dose-response relationship. Furthermore, the bradykinin priming effect was blocked by the PKC inhibitors, bisindolylmaleimide I and chelerythrine. Collectively, these data support prior in vitro findings that, although present on primary sensory neurons, peripheral opioid receptor systems are functionally inactive under basal conditions and require activation of a PKC- and arachidonic acid-dependent signaling pathway to develop functional competence in vivo.
AB - Although centrally acting opioid analgesics produce profound antinociception under basal conditions, the antinociceptive properties of peripherally restricted opioid analgesics are generally only detectable after inflammation or injection of inflammatory mediators. Despite considerable research, the cellular mechanisms regulating the functional competence of peripheral opioid receptor systems for inhibition of nociception remain unclear. Recent work has demonstrated that brief pre-treatment (priming) with bradykinin, arachidonic acid, protease-activated receptor-2 agonists, or direct activators of protein kinase C (PKC) are capable of inducing the functional competence of the opioid receptor system in cultures of primary sensory neurons in vitro. Here we report that the peripheral delta opioid receptor system also requires PKC-dependent priming to inhibit prostaglandin E2 (PGE2)-induced thermal allodynia in the rat. Peripheral hindpaw injection of [D-Pen2,5]-enkephalin (DPDPE), a selective delta opioid receptor agonist, did not alter PGE2-induced thermal allodynia. However, following priming (15 min) with bradykinin or arachidonic acid, DPDPE produced a significant reduction in allodynia that was antagonist reversible, peripherally restricted, and exhibited a typical dose-response relationship. Furthermore, the bradykinin priming effect was blocked by the PKC inhibitors, bisindolylmaleimide I and chelerythrine. Collectively, these data support prior in vitro findings that, although present on primary sensory neurons, peripheral opioid receptor systems are functionally inactive under basal conditions and require activation of a PKC- and arachidonic acid-dependent signaling pathway to develop functional competence in vivo.
KW - Allodynia
KW - Bradykinin
KW - DPDPE
KW - Hindpaw
KW - Prostaglandin
UR - http://www.scopus.com/inward/record.url?scp=58149159544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149159544&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2008.11.028
DO - 10.1016/j.ejphar.2008.11.028
M3 - Article
C2 - 19063879
AN - SCOPUS:58149159544
SN - 0014-2999
VL - 602
SP - 283
EP - 287
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2-3
ER -